AU2021102656A4 - A method and compositions for treatment of alzheimer’s disease - Google Patents
A method and compositions for treatment of alzheimer’s disease Download PDFInfo
- Publication number
- AU2021102656A4 AU2021102656A4 AU2021102656A AU2021102656A AU2021102656A4 AU 2021102656 A4 AU2021102656 A4 AU 2021102656A4 AU 2021102656 A AU2021102656 A AU 2021102656A AU 2021102656 A AU2021102656 A AU 2021102656A AU 2021102656 A4 AU2021102656 A4 AU 2021102656A4
- Authority
- AU
- Australia
- Prior art keywords
- selenium
- treatment
- strain
- enriched yeast
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title abstract description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 49
- 239000011669 selenium Substances 0.000 claims abstract description 49
- 229940091258 selenium supplement Drugs 0.000 claims abstract description 49
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 44
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 238000000855 fermentation Methods 0.000 claims abstract description 15
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000001963 growth medium Substances 0.000 claims abstract description 12
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 12
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 12
- 239000011781 sodium selenite Substances 0.000 claims abstract description 12
- 238000012216 screening Methods 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000021563 Alzheimer disease 1 Diseases 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- JULROCUWKLNBSN-UHFFFAOYSA-N selenocystine Chemical compound OC(=O)C(N)C[Se][Se]CC(N)C(O)=O JULROCUWKLNBSN-UHFFFAOYSA-N 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A METHOD AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S
DISEASE
Aspects of the present disclosure relate to a method (100) for preparation of selenium
5 enriched yeast for the treatment of Alzheimer disease. The said method (100) comprising
the steps of: activating (102), bacteria from the strain slant are activated for preparation of
the selenium-enriched yeast. Then culturing (104), the strain is inoculated in a culture
medium for at least 6 hours, wherein the culture medium is maintained at 30 degree Celsius.
After culturing (104) we do screening (106), the cultured strain by adding sodium azide,
10 wherein after adding the sodium azide of content 20 mol/L, treatment using 0.5 % hydrogen
peroxide, washing and centrifuging is performed on the cultured strain. Finally fermenting
(108), sodium selenite fermentation liquor is added to the cultured strain after screening
(106) to obtain selenium-enriched yeast, wherein the cultures strain is fermented for at least
40 hours. The selenium-enriched yeast is used for prophylactic treatment of Alzheimer
15 disease.
(Fig. 1 will be the reference figure)
20
-9 -
rage i 01 1
100
Activating the Bacteria102
Culturing the strain after activation
|~ 10
Screening of cultured strain followed by treatment,
washing and centrifuging. 106
Fermenting the screened cultured strain 108
Fig. 1 Flowchart of method for preparation of selenium-enriched yeast for the treatment of
Alzheimer disease
1
Description
rage i 01 1
100
Activating the Bacteria102
Culturing the strain after activation |~ 10
Screening of cultured strain followed by treatment, washing and centrifuging. 106
Fermenting the screened cultured strain 108
Fig. 1 Flowchart of method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease
[0001] The present disclosure relates to a composition for treatment of Alzheimer disease and in particular to a method and compositions for diagnosis and treatment of Alzheimer's disease.
[0002] Alzheimer's disease is a progressive brain disease that destroys memory and other important mental functions. Symptoms in Alzheimer's disease includes memory loss, language problems, and unpredictable behavior. One of the main feature of the Alzheimer's disease is loss of connection between nerve cells, which are neurons, in the brain. As, neurons transmit messages between different parts of the brain, between brain and muscles, and between brain and organs in the body, many complex functions as well as simple function of the body are affected. The medications for treatment of mild Alzheimer's disease are galantamine, rivastigmine, and donepezil. Severe Alzheimer's disease is treated by prescribing medications known as memantine, and N-methyl D-aspartate (NMDA) antagonist.
[0003] Selenium is a very important element to the human body in order to perform normal physiological function. Selenium can prevent and inhibit tumors, aging, arteriosclerosis and coronary heart disease.
[0004] Yeast is a microorganism widely used by human body. It has high protein content (as high as 50%), and it is also rich in vitamin B. Selenium-enriched yeast means addition of selenium in the process of cultivating yeast.
[0005] Generally, the selenium-enriched yeast culture is performed by adding sodium selenite during the cultivation process of Saccharomyces cerevisiae. However, in this process, the cell selenium content is low. The amount of selenium and the conversion rate of organic selenium can be optimized in terms of strain screening and selenium-enriched culture.
[00061 Efforts have been made in the related prior art to provide different solutions for treatment of Alzheimer's disease. For example, China Patent no. CN102764279A, talks about the use of selenium yeasts in the treatment of Alzheimer's disease. It relates to compositions and methods for altering cell function. In particular, it provides compositions comprising selenium and methods of using the same. The invention has its scope focusing on change gene, inspection gene etc.
[00071 Efforts have also been made in other related prior art to provide different solutions for treatment of Alzheimer's disease. For example, China Patent no. CN112481143A relates to relates to a method for preparing selenium-enriched yeast. One of the most beneficial feature of this method is use of sodium azide to treat yeast. But, the concentration of sodium azide used is low and the method has a scope of advancement.
[0008] It is an object of the present disclosure, which provides a method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease.
[0009] The present concept of the present invention is directed towards the method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease.
[0010] In an aspect, the present invention further discloses that the said method comprising the steps of: activating the bacteria, culturing, screening, and fermenting.
[0011] In an aspect, bacteria from the strain slant are activated for preparation of the selenium-enriched yeast.
[0012] In another aspect, the strain is inoculated in a culture medium for at least 6 hours and the culture medium is maintained at 30 degrees Celsius.
[00131 In another aspect, the cultured strain by adding sodium azide, with the content of 20 mol/L and after adding the sodium azide, treatment, washing and centrifuging is performed on the cultured strain. The treatment of the cultured strain is done using 0.5% hydrogen peroxide.
[0014] In yet another aspect, sodium selenite fermentation liquor is added to the cultured strain after screening to obtain selenium-enriched yeast, wherein the cultures strain is fermented for at least 40 hours. During the fermentation, the sodium selenite fermentation liquor of 7.5 ug/ml concentration is added initially and after 10 hours the sodium selenite fermentation liquor of 17.5 ug/ml concentration is added.
[0015] FIG. 1 illustrates an exemplary flowchart of method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease.
[0016] In an embodiment of the present disclosure, Alzheimer's disease is a progressive brain disease that destroys memory and other critical mental functions. Symptoms of Alzheimer's disease include memory loss, language problems, and unpredictable behaviour. It is found that in the brain of a person who has Alzheimer's disease, there are many abnormal clumps, called amyloid plaques, and tangled bundles of fibres, called neurofibrillary, or tangles. They are considered as few of the main features of Alzheimer's disease. Also, there is a loss of connection between nerve cells, which are neurons, in the brain. As neurons transmit messages between different parts of the brain, between the brain and muscles, and between the brain and organs in the body, many complex functions and simple function of the body are affected. The medications for the treatment of mild Alzheimer's disease are galantamine, rivastigmine, and donepezil. Severe Alzheimer's disease is treated by prescribing medications known as memantine and N-methyl D-aspartate (NMDA) antagonist.
[00171 In an embodiment of the present disclosure, Selenium is an essential element to the human body in order to perform the normal physiological function. The human body absorbs selenium through its regular diet, which has selenium of different content. Selenium mixes with different organic molecules comprising of aminoacids, such as 1 selenomethionine, selenocysteine and DL-Selenocystine. Selenium can be a proteinic ingredient and is important to body structure. Selenium can prevent and inhibit tumors, aging, arteriosclerosis and coronary heart disease. Deficiency of selenium leads to Keshan disease and osteogenic disease and cataracts, liver disease and pancreas adenopathy, etc.
[0018] In another embodiment of the present disclosure, yeast is a microorganism widely used by the human body. It has high protein content (as high as 50%), and it is also rich in vitamin B. Selenium-enriched yeast means the addition of selenium in the process of cultivating yeast. Selenium is organically combined with proteins and polysaccharides present in yeast. This combination eliminates toxic side effects on the human body. Generally, the selenium-enriched yeast culture is performed by adding sodium selenite during the cultivation process of Saccharomyces cerevisiae.
[0019] In an embodiment of the present disclosure, Fig. 1 is a flowchart illustrating a method (100) for preparation of selenium-enriched yeast for the treatment of Alzheimer disease. The said method comprises the steps of: activating the bacteria (102), culturing (104), screening (106), and fermenting (108).
[0020] In an aspect of the present disclosure, a group of strain is picked up from a strain slope and the bacteria from the strain slant are activated (102) for preparation of the selenium-enriched yeast. Activation is due to some factors that interact at specific promoters. Therefore, activation results in an increase in transcription at these promoters.
[0021] In another aspect of the present disclosure, culture media, which is also known as growth media, are specific mixtures of nutrients and other substances. Culture media support the growth of microorganisms such as bacteria and fungi (yeasts and molds). They are used for quality control tests of raw materials and finished products and also for microbial contamination tests. In this aspect, the strain is inoculated in a culture medium (104) for at least 6 hours, wherein the culture medium is maintained at 30 degrees Celsius. Here, Inoculation is a process of adding effective bacteria to the host before it starts growing. The purpose of inoculation is to make sure that there is enough of the correct type of bacteria present so that a successful legume-bacterial symbiosis is established.
[0022] In another aspect of the present disclosure, after the activated strains are cultured on a shaker for 6 hours, as in previous aspects, sodium azide is added (106) to the cultured strain. After adding sodium azide treatment, washing and centrifuging is performed on the cultured strain.
[00231 Sodium azide slows the growth of Saccharomyces cerevisiae, and it also induces a lag. This lag induced increases steeply with the increase in the concentration. There is an emergence of a more resistant adapted strain due to serial transfer. One of the most beneficial features of this method is sodium azide in the treatment of yeast and at a higher content level. The content of sodium azide is 20mol/L. In this aspect of the present disclosure, the treatment done after adding sodium azide is done using 0.5% hydrogen peroxide.
[0024] In the same aspect of the present disclosure, the centrifugation step sets aside the cells from the staining suspension. It thus permits the removal of the supernatant fluid from the suspension. After centrifugation, washing of unbound antibody from the cells is done. The unbound antibody is removed by dilution. It is done in multiple sequential washing steps.
[0025] Yet another aspect of the present disclosure involves the process of fermentation (108). Fermentation is a chemical breakdown of a substance by some bacteria, yeasts, or other microorganisms. It typically involves effervescence and the gives off heat. In this process, sodium selenite fermentation liquor is added to the cultured strain after screening to obtain selenium-enriched yeast, wherein the cultures strain is fermented for at least 40 hours. During the fermentation, the sodium selenite fermentation liquor of 7.5 ug/ml concentration is added initially and after 10 hours the sodium selenite fermentation liquor of 17.5 ug/ml concentration is added.
[0026] In an aspect, under this method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease, the selenium-enriched yeast is used for prophylactic treatment of Alzheimer disease. A prophylactic treatment is a medication or a treatment designed to and used to prevent a disease from occurring.
Claims (6)
1. A method (100) for preparation of selenium-enriched yeast for the treatment of Alzheimer disease, said method comprising the steps of:
Activating (102), bacteria from the strain slant are activated for preparation of the selenium-enriched yeast;
Culturing (104), the strain is inoculated in a culture medium for at least 6 hours, wherein the culture medium is maintained at 30 degree Celsius;
Screening (106), the cultured strain by adding sodium azide, wherein after adding the sodium azide, treatment, washing and centrifuging is performed on the cultured strain;
Fermenting (108), sodium selenite fermentation liquor is added to the cultured strain after screening (106) to obtain selenium-enriched yeast, wherein the cultures strain is fermented for at least 40 hours.
2. The method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease as claimed in claim 1, wherein the content of the sodium azide is 20 mol/L.
3. The method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease as claimed in claim 1, wherein the treatment of the cultured strain is done using 0.5% hydrogen peroxide.
4. The method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease as claimed in claim 1, wherein after cleaning, washing and centrifugation, strain is transferred to a new liquid culture medium, culture in a shake flask at 28-30 degree Celsius for 6 hours.
5. The method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease as claimed in claim 1, wherein during the fermentation, the sodium selenite fermentation liquor of 7.5 ug/ml concentration is added initially and after 10 hours the sodium selenite fermentation liquor of 17.5 ug/ml concentration is added.
6. The method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease as claimed in claim 1, wherein the selenium-enriched yeast is used for prophylactic treatment of Alzheimer disease.
Total no. of sheets: 1 18 May 2021 2021102656 Page 1 of 1
Fig. 1 Flowchart of method for preparation of selenium-enriched yeast for the treatment of Alzheimer disease
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021102656A AU2021102656A4 (en) | 2021-05-18 | 2021-05-18 | A method and compositions for treatment of alzheimer’s disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021102656A AU2021102656A4 (en) | 2021-05-18 | 2021-05-18 | A method and compositions for treatment of alzheimer’s disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021102656A4 true AU2021102656A4 (en) | 2021-07-08 |
Family
ID=76662611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021102656A Ceased AU2021102656A4 (en) | 2021-05-18 | 2021-05-18 | A method and compositions for treatment of alzheimer’s disease |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021102656A4 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794303A (en) * | 2022-05-10 | 2022-07-29 | 吉林省农业科学院 | Selenium-rich rhodotorula mucilaginosa, selenium-rich rhodotorula mucilaginosa feed additive and preparation method and application thereof |
-
2021
- 2021-05-18 AU AU2021102656A patent/AU2021102656A4/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794303A (en) * | 2022-05-10 | 2022-07-29 | 吉林省农业科学院 | Selenium-rich rhodotorula mucilaginosa, selenium-rich rhodotorula mucilaginosa feed additive and preparation method and application thereof |
| CN114794303B (en) * | 2022-05-10 | 2023-07-14 | 吉林省农业科学院 | Selenium-enriched rhodotorula mucilaginosa, selenium-enriched rhodotorula mucilaginosa feed additive, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Son et al. | Optimization of fermentation conditions for the production of bacterial cellulose by a newly isolated Acetobacter | |
| Nguyen et al. | Characterization of cellulose production by a Gluconacetobacter xylinus strain from Kombucha | |
| JP6722799B2 (en) | Method for producing enzyme solution of low-sugar vegetables and/or fruits | |
| CN107012103B (en) | Low-yield fusel oil yeast and application thereof in mechanical production of Xiaoqu raw wine | |
| Hajar-Azhari et al. | Evaluation of a Malaysian soy sauce koji strain Aspergillus oryzae NSK for γ-aminobutyric acid (GABA) production using different native sugars | |
| KR20090129068A (en) | Novel gluconacetobacter sp. c1 strain and a production method of cellulose using thereof | |
| Melzoch et al. | Lactic acid production in a cell retention continuous culture using lignocellulosic hydrolysate as a substrate | |
| AU2021102656A4 (en) | A method and compositions for treatment of alzheimer’s disease | |
| Jiang et al. | Studies on screening of higher γ-aminobutyric acid-producing Monascus and optimization of fermentative parameters | |
| CN110564580B (en) | Method for producing vinegar containing pyrroloquinoline quinone through microbial co-culture fermentation | |
| CN110317734A (en) | A kind of monascus and its isolated culture method and the application of high-yield glucoamylase, Esterified Enzyme and protease | |
| CN106497982A (en) | A kind of α glucosidase inhibitors and preparation method thereof | |
| CN103214593A (en) | Preparation method of beta-glucan | |
| CN109234199A (en) | A kind of caproic acid bacterium culture medium containing liquor fermentation process raw material and its application | |
| CN114404344B (en) | Yeast/barley seed fermentation product, product containing same and preparation method and application thereof | |
| CN107760724A (en) | A kind of method and the α glucosidase inhibitors that α glucosidase inhibitors are prepared using Paenibacillus polymyxa | |
| CN107164136A (en) | The fermentation process of low volatile acid grape wine | |
| CN106754089A (en) | A kind of technique of use meat ganoderma lucidum soak wine brewing | |
| KR20030040605A (en) | An Ethanol-tolerant Strain, Saccharomyces cerevisiae SE211 and The Process For Manufacturing Rice Wine Using This Strain | |
| CN104711304A (en) | Method for producing germ nano-crystalline cellulose by utilizing tea fungus and raffinose | |
| CN104531570B (en) | A kind of Acinetobacter bauamnnii for producing laccase and the methods and applications for producing laccase | |
| CN109401990B (en) | Saccharomyces cerevisiae HKB-36 with bacteriostatic activity and application thereof | |
| JP2006000025A (en) | New yeast and method for producing sake therewith | |
| CN105368753B (en) | A kind of production method of inosine bacterial strain | |
| CN106811486A (en) | A kind of orange peel extractive from fermentative and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |